It is also possible that this group would benefit more from novel redifferentiation drugs ahead of radioiodine therapy, such as MEK and BRAF inhibitors, which have shown an ability to restore and increase iodine avidity in thyroid cancer [26,27,28]. The gene discussed is MAP2K7; the disease is thyroid cancer.